Pain Management · OpioidRegulatory Approvalcommercialmid-term

Hikma's ANDA090964 for Oxymorphone Hydrochloride Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma18 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 7:00:46 AM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

Hikma's receipt of AP status for Oxymorphone Hydrochloride signals an impending entry into the competitive opioid market. This could disrupt pricing and market share dynamics for existing players in the pain management segment, necessitating strategic adjustments. Regulatory context from FDA (FDA AP — OXYMORPHONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Hikma's potential entry on pricing and market share for existing opioid products. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 4 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). Secondary pressure from [Ad hoc announcement pursuant to Art.. This AP status indicates that Hikma is closer to entering the market with a generic version of Oxymorphone Hydrochloride, potentially increasing competition in the opioid pain management segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — OXYMORPHONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). While the AP status indicates progress, it does not yet confirm final approval, meaning regulatory risks remain low at this stage.

Key Opportunities

The introduction of Hikma's generic product may lead to price reductions and increased competition, potentially impacting revenue for current opioid manufacturers.
Portfolio teams should assess the impact of Hikma's potential entry on pricing and market share for existing opioid products.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval status and market launch timeline for ANDA090964.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — OXYMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (oxymorphone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalslow relevance
Sponsor/company relevance (Merck)

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Oxymorphone Hydrochloride

Commercial impact

medium

The introduction of Hikma's generic product may lead to price reductions and increased competition, potentially impacting revenue for current opioid manufacturers.

Regulatory impact

low

While the AP status indicates progress, it does not yet confirm final approval, meaning regulatory risks remain low at this stage.

What to watch

Monitor the final approval status and market launch timeline for ANDA090964.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.